Zura Bio Ltd

Zura Bio Ltd (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company focused on immunology and inflammatory disease that entered the public markets through a SPAC business combination in 2023. The company develops novel therapeutics targeting autoimmune conditions and has maintained its Nasdaq listing since completing its de-SPAC transaction. Zura Bio filed an 8-K with the Securities and Exchange Commission on August 17, 2026 (accession 0001104659-26-097526), continuing its standard disclosure obligations as a public company in the biotechnology sector. The filing reflects ongoing corporate activity as Zura advances its clinical pipeline. Investors and analysts seeking full SEC filing history, corporate event timelines, and institutional data on ZURA can access complete coverage by signing up at SpacDesk.